Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

First Rand Foundation contributes funding towards students with disabilities
2017-01-02

 Description: First Rand Foundation Tags: First Rand Foundation

Photo: iStock

Bursary funding for eight students with disabilities at the University of the Free State was recently approved by the First Rand Foundation. The grant of R2 497 440 will be paid over three years: R800 000 (2016/17), R824 000 (2017/18), and R873 440 (2018/19).

This grant from the First Rand Tertiary Education Fund is a result of the negotiations between the UFS Office for Institutional Advancement and the First Rand Foundation (FRF).

Qualifying students with disabilities will be encouraged to apply for bursaries according to criteria and requirements set by the First Rand Foundation. The selection process will be handled by a panel from the UFS. The Centre for Universal Access and Disability Support (CUADS) at the UFS will be instrumental in the process of identifying students with disabilities who meet the criteria and requirements for funding.

CUADS already have a system in place to support students with disabilities in their studies and during exams. Students also have access to specialised exam and test venues for alternative test and exam procedures, as well as computer facilities.

Specialised support services include an amanuensis (scribe) service during tests and exams, accommodating extra time, individual tutor sessions provided in collaboration with the Centre for Teaching and Learning, South African Sign Language interpreter coordination, provision of accessible study material, and individual disability support.

 

“The centre aims to ensure that the university increasingly becomes a universally accessible environment that is welcoming and accepting to people with diverse abilities.”

According to Martie Miranda, Head of CUADS, the centre aims to ensure that the university increasingly becomes a universally accessible environment that is welcoming and accepting to people with diverse abilities. “Therefore disability awareness training and advocacy within the UFS, and specifically among staff members, is one of our priorities,” she said.

According to Thandeka Rantsi from the FRF, the company will furthermore support students in CUADS with regards to the needs ensuing from the #feesmustfall protests. “Exactly R34 000 was approved by the FRF for 14 students towards residence and meal expenses, as well as scribe and reader assistance during additional assessments,” she said.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept